Biotech Breakthrough Sparks 150% Surge

Author

Adam Garcia
March 28, 2025

​

A biotech stock is surging 150% on promising cancer therapy results, a small-cap pharma firm just struck a billion-dollar licensing deal with a global obesity drug giant, and a biotech firm is rising on entering the commercial market. Here’s what you need to know.

Health & Wellness (Sponsored)

In the early 2000s, Monster Beverage quietly entered the scene—then exploded 137,100%, turning $1,000 into $1.37 million. Now, a new contender could be on a similar path.

A tiny beverage company has developed what could be the first functional energy drink of its kind: one designed not just for energy, but for enhanced focus and mental clarity. It's packed with patented nootropics—and early results are turning heads.

With the functional beverage market now worth over $73 billion and growing fast, this under-the-radar company could be perfectly positioned to ride the next big wave.

Futures 📈

What to Watch

Earnings:

  • Xos, Inc. [XOS]: Aftermarket

Economic Reports:

  • Personal income [Feb]: 8:30 a.m.

  • Personal spending [Feb]: 8:30 a.m.

  • PCE index [Feb]: 8:30 a.m.

  • Core PCE index [Feb]: 8:30 a.m.

  • Consumer sentiment (final) [March]: 10:00 a.m.

  • Fed Governor Michael Barr will speak at 12:15 p.m.

  • Atlanta Fed President Raphael Bostic will speak at 3:30 p.m.

Beverage Industry (Sponsored)

Tech and AI stocks may grab headlines, but history shows some of the biggest investment gains come from unexpected places. 

Take Monster Beverage—since 2000, it’s delivered an astonishing 137,100% return, outperforming even the biggest tech names.

Now, a new functional beverage company is making waves with a powerful energy drink infused with nootropics.

Could it be the next breakout success?as

Aesthetic Healthcare

SBC Medical Eyes Expansion Despite Q4 Profit Drop, FY24 Revenue Rises

SBC Medical Group Holdings Inc. (NASDAQ: SBC) reported mixed financial results for the fourth quarter but has closed fiscal 2024 with steady growth and ambitious plans for global expansion.

The company posted Q4 revenue of $44 million, down 29% from the same period last year.

Net income is down 54% to $7 million, while earnings per share are $0.06, down 58% year-over-year.

Operating income declined sharply by 80%, though EBITDA margin improved to 47%.

For the full year, SBC reported revenue of $205 million, a 6% increase, driven by the expansion of its franchise network.

Net income is up 18% to $47 million, with earnings per share rising to $0.48. Customer numbers reached 6.03 million, up 15%, while the repeat customer rate held strong at 71%.

The group now operates 251 clinics, 43 more than a year earlier.

In 2025, the company plans to revise its franchise fee model to ease startup burdens and better align fees with clinic performance.

It also expects to offset any revenue hit from the new structure with cost savings from reduced one-time expenses.

SBC Medical aims to strengthen its leadership in Japan's aesthetic healthcare market and expand its presence across Asia through its recent acquisition of Singapore-based Aesthetic Healthcare Holdings.

Biotechnology

Humacyte Reports Wider Annual Loss, Eyes Dialysis and Cardiac Trials

Biotech firm Humacyte (NASDAQ: HUMA) posted no revenue for the fourth quarter or the full 2024 fiscal year.

However, Humacyte has officially entered the commercial market, launching its first sales of Symvess™ in February 2025 following FDA clearance in December for treating vascular trauma in limbs.

The company says 34 hospitals have begun their internal approval process for Symvess, with three institutions already granting purchase clearance.

Humacyte stock is up nearly 4% in early trade.

Research and development spending totaled $88.6 million for the year, while the company’s net loss widened to $148.7 million, up from $110.8 million in 2023.

As of the end of December, the company held $95.3 million in cash and equivalents.

That figure was bolstered by a $46.6 million public offering completed in March 2025, which will help fund future product development and commercial operations.

The company also reported promising Phase 3 results for its arteriovenous access product designed for dialysis patients and plans to file a supplemental Biologics License Application in the second half of 2026.

Additionally, an Investigational New Drug (IND) application is expected later this year for the use of its bioengineered vessels in coronary artery bypass surgery.

Next-Gen Display Tech (Sponsored)

Remember when OLED's IPO at $6 soared to $252.69, a 4,090% gain?

A pioneering company has the potential to deliver the next generation of MicroLED displays, a sector projected to reach $21 billion by 2027.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Automotive Parts

CAAS Sees Strong Sales Momentum Ahead After Mixed Q4 Results

China Automotive Systems, Inc. (NASDAQ: CAAS) announced its fourth-quarter results, reporting lower earnings but stronger revenue growth while projecting an increase in full-year sales for 2025.

The auto parts manufacturer posted a net income of $9.1 million, or $0.30 per share, for the quarter ending December 31, down from $10.9 million, or $0.36 per share, in the same period a year ago.

The earnings dip comes despite a significant boost in quarterly revenue, which rose 18.6% to $188.7 million from $159.2 million in the prior-year quarter.

The company attributes the revenue growth to stronger demand for both passenger and commercial vehicles, along with favorable shifts in its product lineup.

Looking ahead, China Automotive Systems projects fiscal 2025 revenue to reach $700 million, up from the $650.9 million recorded in 2024.

The company remains optimistic about continued expansion as vehicle production in China and overseas markets shows signs of recovery.

The announcement comes as global auto demand continues to rebound, with component suppliers like CAAS focusing on product innovation and capacity scaling to meet rising orders.

Movers and Shakers

Portage Biotech Inc. [PRTG] - Last Close: $4.71

Portage Biotech is a clinical-stage immuno-oncology company focused on developing novel immune-enhancing therapies for cancer.

Shares are jumping nearly 150% in premarket after the company announced promising preclinical results in mesothelioma using its A2B receptor inhibitor, PORT-7.

My Take: Early-stage data like this can drive massive interest, but wait for clinical trial results to validate these promises. Keep this on your radar for sure.

Lexicon Pharmaceuticals, Inc. [LXRX] - Last Close: $0.35

​Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing treatments for human diseases, including metabolic disorders.​

The stock is rising 83% in premarket trading today following the announcement of an exclusive license agreement with Novo Nordisk for LX9851, a first-in-class, oral non-incretin development candidate targeting obesity and associated metabolic disorders.

Under the terms of the agreement, Lexicon will receive $75 million in upfront and near-term milestone payments, with the potential for up to $1 billion in total payments, plus royalties on net sales. ​

My Take: This partnership with Novo Nordisk provides Lexicon with significant financial resources.​ However, the stock has been falling for quite some time and struggling to attain profitability. Keep it on your wait and watch list.

Dolphin Entertainment, Inc. [DLPN] - Last Close: $1.06

Dolphin Entertainment is a creative entertainment marketing and content production company.

Its shares are surging 11% in early trading after the company reported a 20% year-over-year revenue jump to $51.7 million in FY 2024 and turned an adjusted operating profit of $0.9 million—up from a $2.4 million loss the year before.

My Take: Dolphin's return to profitability and strong top-line growth signal a positive turnaround. If it maintains this momentum, this could be a great stock to keep on your radar.

Next-Gen Consumer Brands (Sponsored)

Monster Beverage shocked the market with a 137,100% return—beating Amazon, Apple, and even Tesla.

It’s not just another energy drink. This one’s infused with nootropics designed to support focus, clarity, and mood—exactly what today’s health-conscious consumers are demanding.

And the company behind it just brought on Orangetheory Fitness co-founder David Long as a board member. That kind of leadership rarely comes without serious conviction.

With a unique product, a booming category, and a proven industry heavyweight backing the mission, this could be the next beverage breakout story.

Everything Else

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.

*Standard message/carrier rates may apply.

Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails.